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SUMMARY
The aim of this paper is to describe the auditory profile of subjects who were given streptomycin treatment for tuberculosis in
the years 2000 and 2001, in Recife, Northeast Brazil. The Injury Notification Database at the Municipal Department of Health was
consulted and 78 individuals who had been on streptomycin during the period under study were selected. Forty-two individuals
were excluded, of whom five were over 59 years of age and two were under 18 years. Nineteen turned out to be deceased, 13 could
not be found, two were serving prison terms and one refused to participate. As a result, only 36 subjects participated in the study.
These 36 individuals were interviewed and underwent meatoscopy and audiometry. The mean age of the group under study was
38.8 years old and males predominated (79.4%). Twenty-seven patients (75%) showed hearing impairment, the bilateral sensorineural
type (63.9%) being the most frequent, mainly affecting the high frequencies over 4000 Hz. In the light of findings showing a high
percentage of hearing impairment complaints among users of streptomycin, this issue seems to warrant an in-depth investigation,
as does the implementation of an auditory follow-up routine for patients undergoing such chemotherapy for tuberculosis.
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INTRODUCTION
Tuberculosis is still considered to be a public health issue. Its
treatment is based mainly on chemotherapeutic agents. In Brazil, the
Ministry of Health’s National Program for Tuberculosis Control has
established four standardized treatments3. Streptomycin is probably
the best and most effective aminoglycoside drug still in use against
tuberculosis11, being employed in Brazil when prior treatments have
failed to deliver3.
There are many studies reporting adverse reactions to tuberculosis
treatment12,15,17. To mention just two: patients using streptomycin have
been reported to suffer from hypoacusis and dizziness10,14.
Health-care workers prescribing or following up aminoglycoside
treatment are expected to ask their patients about auditory and vestibular
signs and symptoms in order to identify any alterations at an early
stage, since hearing loss may turn out to be gradual and irreversible5,8.
Recife, Northeast Brazil, despite the decreased incidence of
tuberculosis over the past few years, has been classified as being of
high risk for this disease since 2002, accounting for 32.5% of the total
number of cases in the state. When they quit tuberculosis treatment,
patients are often forced to resume it, using more toxic drugs, and
even worse, for a longer period of time13.
A study, carried out in the municipality of Recife, in 1997, revealed
that 16.2% of tuberculosis cases were undergoing treatment. Cessation
of therapy was the main reason for retreatment, 42% of cases having1
undergone two or more previous treatments.
Given these facts, the aim of the present study was to evaluate the
auditory profile of individuals who had undergone streptomycin
treatment for tuberculosis in the years 2000 and 2001 in the municipality
of Recife.
METHODS
This was a case series study covering patients treated with
streptomycin for tuberculosis during 2000 and 2001 in Recife. The
patients had received streptomycin sulfate at the defined daily doses,
ranging from 15 to 20 mg/kg/day3. The Injury Notification Database,
provided by the municipality’s Health Department, was consulted and
cases selected. The criterion for inclusion was: individuals between 18
and 59 years-old registered in the Injury Notification Database with
tuberculosis who received streptomycin treatment for at least 15 days
during the period under study.
This survey showed that 78 individuals had received streptomycin
treatment. Forty-two individuals were excluded, of whom five were
over 59 years of age and two were under 18 years. Nineteen turned out
to be deceased, 13 could not be found, two were serving prison terms
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and one refused to participate. As a result, only 36 subjects participated
in the study.
Information on the length of treatment was obtained from each
patient by way of an interview. It was not possible to confirm these
data in the Health Department records on account of the unreliability
of the records or failure to trace the patient’s history. Since the
administration of streptomycin is parenteral and daily, it seems unlikely
that there was any bias in this information. During the interview,
participants were also questioned about any hearing difficulties they
may have experienced prior to using streptomycin.
Home visits were scheduled so that subjects could be made aware
of and encouraged to participate in the research, which included tests
at the Audiology Clinic of the Audiometry and Phoniatrics Course at
the Federal University of Pernambuco.
Auditory impairment was identified on the basis of both on the
patient’s complaints and the disturbances detected by audiometry. Pure-
tone audiometry was carried out for the airways at frequencies 0.25; 1;
2; 3; 4; 6; 8; and 12 kHz and for bone conduction at frequencies 0.5; 1;
2; 3 and 4 kHz. The 12 kHz frequency was used, because, according to
the literature, ototoxic alterations are easier recognized at higher
frequencies4. Evaluations were performed using a two-channel
audiometer (Damplex, model 65) calibrated to the ANSI 53.6 standard
and TDM 39 phones. Auditory thresholds at or below 20 dB HL were
considered normal. The absolute and relative distributions were
obtained for data analysis.
The average and the standard deviations were calculated for a few
numerical variables. The following tests were used for statistical
analysis: Fisher’s exact test, the Wilcoxon Sign Rank test, and the
Student’s t test.
The subjects were enrolled on the study after signing an informed
consent form. Every individual received his/her exam results and an
otolaryngological follow-up was guaranteed for those exhibiting hearing
loss. The present project has been approved by the Centro de Pesquisas
Aggeu Magalhães (CPqAM/FIOCRUZ) Ethics Committee.
RESULTS
Of the 36 subjects who participated in the study, 27 (75%) were
males and nine (25%) females. The age of the patients ranged from 27
to 57 years, with a mean of 38.8 years.
Auditory disorders were identified in 27 individuals (75%),
sensorineural hearing loss being the most frequent type of disorder
(23 patients). Those without hearing loss represented one quarter of
the study sample. Conducive and other forms of hearing impairment
were seen in two cases each.
The audiometric examinations for frequencies up to 3,000 Hz
showed means ranging between 16 and 18 dB HL in the right ear, and
between 14 and 20 dB HL in the left ear. For frequencies from 4,000 to
12,500 Hz, the means ranged between 22 and 46 dB HL in the right
ear, and between 21 and 38 dB HL in the left ear. Comparing right and
left ears, the largest mean differences occurred at 12,500 Hz, 8,000 Hz
and 1,000 Hz, the highest values being found in the right ear. Except
for the 3,000 Hz and 6,000 Hz frequencies, all other mean values were
higher in the right ear, and at 12,500 Hz, the right ear was significantly
impaired compared to the left (p < 0.01) (Table 1).
The audiometric measurements according to the type of frequency,
low or high, per individual ear, demonstrated that the mean audiometric
values were significantly higher at the high frequencies than at the
lower ones (p < 0.01) (Table 2).
Fifty percent of the study participants had received treatment for a
period of more than two months, while the remainder had been treated
for shorter periods of time. However, differences in hearing impairment
between these groups were not significant (77.8% versus 72.2,
respectively) (Table 3).
Individuals between 40 to 59 years-old exhibited higher percentages
of hearing loss (81.3%) than those between the ages of 20 to 39 (70%),
(p > 0.05), as depicted in Table 4. Most patients (77.8%) had not
complained of hearing loss prior to treatment with streptomycin. The
Table 1
Summary audiometric data, for each ear, of individuals using streptomycin for
tuberculosis treatment, during 2000 and 2001 in Recife
Frequency       Statistical data Ear
(Hz) Right Left p value
250 Mean (3) 18.13 17.42 p (1) = 0.5410
Standard deviation (3) 8.01 7.19
Variation coefficient (%) 44.18 41.29
500 Mean 16.25 15.61 p (1) = 0.4782
Standard deviation 7.73 7.26
Variation coefficient (%) 47.54 46.54
1,000 Mean 16.88 14.70 p (1) = 0.1153
Standard deviation 8.30 6.95
Variation coefficient (%) 49.21 47.31
2,000 Mean 16.41 15.91 p (1) = 0.6383
Standard deviation 10.94 11.56
Variation coefficient (%) 66.70 72.63
3,000 Mean 18.59 20.00 p (1) = 0.0918
Standard deviation 13.33 13.92
Variation coefficient (%) 71.71 69.60
4,000 Mean 22.34 21.52 p (2) = 0.6624
Standard deviation 16.51 14.66
Variation coefficient (%) 73.89 68.12
6,000 Mean 30.28 31.06 p (2) = 0.2304
Standard deviation 20.67 17.44
Variation coefficient (%) 68.25 56.16
8,000 Mean 30.00 27.12 p (2) = 0.7721
Standard deviation 24.70 19.57
Variation coefficient (%) 82.33 72.15
12,500 Mean 45.97 38.03 p (1) = 0.0051*
Standard deviation 26.96 25.65
Variation coefficient (%) 58.65 67.44
* Significant difference at p = 0.05; (1) Wilcoxon Sign Rank test; (2) Student’s
paired t test; (3) Mean in dB; Two conductive and two mixed forms of hearing
impairment were excluded.
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patients who had complained of hearing loss prior to treatment showed
16.1% greater hearing impairment than those who had no such
complaints (p > 0.05).
DISCUSSION
Tuberculosis treatment interruption is a source of concern for public
health managers. Usually the long treatment periods, the lack of an
appropriate follow-up and the occurrence of adverse reactions to therapy
lead patients to quit treatment, although afterwards they will be forced
to undergo retreatment. The resumption of treatment frequently entails
subjects having to be put on potentially ototoxic and vestibulotoxic
medication.
The audiometric measurements taken in our study population
showed hearing impairment, although, in most cases, hearing loss was
restricted to the higher frequencies. These results are in accordance
with the data found in the literature, which point out that the higher
the frequency, the more severe is the impairment found. According to
some authors1,2,4, hearing loss due to the use of ototoxic agents is
triggered at high frequencies and, generally, confined to these.
In this study, hearing impairment was found to be bilateral in 62.9%
of the patients. Hearing impairment caused by ototoxic medication is
of the sensorineural uni- or bilateral type9.
The study found that hearing loss was more prevalent in females
and this differs from the data published elsewhere16, in which 80% of
the hearing impairments occurred in males. It should be noted that
most studies on ototoxicity do not mention the patient’s gender as a
risk factor.
Individuals over 59 years of age were excluded from our study due
to the fact that they may display hearing impairments mimicking those
caused by ototoxicity. Somewhat higher percentages of hearing
impairment were found in individuals between 40 and 59 years of age,
a predictable finding, since older people tend to display higher
susceptibility to ototoxic agents14.
Despite the fact that hearing impairment occurred in a high
percentage of subjects, one should not overlook the fact that this group
had very special socioeconomic traits, being made up of alcohol abusers,
unemployed and homeless people and the like. Although socioeconomic
and cultural factors were not analyzed, they are known to influence
the outbreak, exacerbation and persistence of any disease.
The treatment strategy currently recommended by the National
Tuberculosis Control Program is to use streptomycin daily for three
months. In the present study, the minimum period for streptomycin
therapy was 15 days and the maximum, eight months. The duration of
use of any given drug is considered to be an important factor for adverse
reactions. The effects of streptomycin have been analyzed elsewhere
in people who used it for six months. The initial symptoms occurred
during the 4th and 5th weeks of therapy and continued for periods varying
from one week to several months6. In our study there were no significant
differences in hearing impairment between the groups who had received
treatment for more or less than two months. On the other hand, the
effect of the daily dose given to each patient was not studied because
this information was not given either in the database consulted or by
the patients in the interview. Hearing impairment was more commonly
present in those individuals who took streptomycin for more than two
months. In fact, data found elsewhere also associate hearing loss with
the daily dosage and the length of treatment using streptomycin7.
CONCLUSION
The high percentage of hearing impairment found in this population
points to the need for further studies, using larger samples and a study
design with greater analytical power, which could more accurately
reflect the real situation. Every year, streptomycin is prescribed for
about 40 new patients in the municipality of Recife, a number small
enough to allow for systematic follow-up. The implementation of
Table 3
Hearing impairment in people receiving treatment for tuberculosis using
streptomycin throughout treatment in Recife, 2000-2001
Hearing impairment
Duration of treatment Yes No Total
N % N % N %
15 days - 2 months 13 72.2 5 27.8 18 100
> 2 - 8 months 14 77.8 4 22.2 18 100
Total group 27 75.0 9 25.0 36 100
Fisher’s exact test: p = 1.000; Ratio between proportions of loss: RP = 1.08; IC =
(0.74 to 1.57)
Table 4
Hearing impairment in people who underwent treatment for tuberculosis with
streptomycin according to age group, Recife, 2000-2001
Hearing impairment
Age group (years) Yes No Total
N % N % N %
40 - 59 13 81.3 3 18.7 16 100
20 - 39 14 70.0 6 30.0 20 100
Total 27 75.0 9 25.0 36 100
Fisher’s exact test: p = 0.70003; Ratio between proportions of loss: RP = 0.71; CI
+ (0.40 - 1.26).
Table 2
Audiometry in people treated with streptomycin. High and low frequencies for
each ear, Recife, 2000-2001
Audiometry
Statistics Low High p value
Right ear Mean (2) 16.91 27.72 p (1) < 0.001 *
Standard deviation (2) 7.87 18.31
Variation coefficient (%) 46.51 66.06
Left ear Mean 15.91 27.55 p (1) < 0.001 *
Standard deviation 6.76 16.06
Variation coefficient (%) 42.51 58.30
* Significant difference at p = 0.05; (1) Wilcoxon Sign Rank test; (2) Mean in dB;
Two ears with conductive and two with mixed forms of hearing loss were excluded.
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auditory monitoring for patients who undergo treatment with this drug
is therefore recommended. Special attention should be paid to both
the treatment strategy and the complaints reported during treatment.
In this way, possible sequelae may be avoided or lessened, thereby
encouraging greater compliance with the treatment of a disease that
brings social stigma and causes problems of control for the health
system.
RESUMO
Alteração auditiva em pacientes com tuberculose no nordeste do
Brasil
Este trabalho teve por objetivo descrever o perfil auditivo de pessoas
que realizaram tratamento para tuberculose com estreptomicina em
Recife nos anos de 2000 e 2001. Para tal foi utilizado o banco de dados
do Sistema de Informação de Agravos de Notificação, fornecido pela
Secretária de Saúde deste município, sendo selecionadas 78 pessoas
que usaram a droga no período em estudo. Do total de pacientes
selecionados sete eram menores de 18 anos ou maiores de 58 anos, 19
haviam falecido, 13 não foram localizados, dois eram presidiários, um
negou-se a participar, restando, pois 36 indivíduos que puderam ser
submetidos a uma entrevista, a meatoscopia e a audiometria. No grupo
estudado predominou o sexo masculino (79,4%) e a média das idades
era de 38,8 anos. Dos 36 pacientes, 27 (75,0%) apresentaram alteração
auditiva, sendo a mais freqüente a sensório-neural bilateral (63,9%),
com predomínio de freqüências agudas, a partir de 4000 Hz. Os achados
com elevados percentuais de alteração auditiva entre os usuários de
estreptomicina, apontam para a necessidade de aprofundamento deste
tema em outros estudos, e também sugerem a necessidade de
estruturação de um sistema de monitoramento auditivo para a população
de pacientes submetidos a esse quimioterápico no tratamento para
tuberculose.
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